戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  be as effective as TDF, with lower bone and renal toxicity.
2 enofovir disoproxil fumarate (TDF) may cause renal toxicity.
3 f abstinence on ketamine-induced cardiac and renal toxicity.
4 men has a high efficacy, without significant renal toxicity.
5 at submaximally efficacious doses because of renal toxicity.
6 duced expression of fibrogenic molecules and renal toxicity.
7 ssion sometimes complicated by infection and renal toxicity.
8 ase I can cause gastrointestinal, liver, and renal toxicity.
9 ood loss, GI intolerance, hepatotoxicity, or renal toxicity.
10  because of their insolubility and resulting renal toxicity.
11 le cerebral artery in rats and was devoid of renal toxicity.
12 enting progression, avoiding bone marrow and renal toxicity.
13  improve therapeutic efficacy while reducing renal toxicity.
14 d radiopharmaceutical therapy aims to reduce renal toxicity.
15  outweighed the theoretical risk of liver or renal toxicity.
16 atients (21%) demonstrated transient grade 1 renal toxicity.
17  calcineurin inhibitor-mediated neuronal and renal toxicities.
18 toxicities (6.3% v 4.4%; P = .25) and severe renal toxicity (8.9% v 11.2%; P = .47) were comparable i
19                   There were no grade 3 or 4 renal toxicities and no treatment-related deaths.
20 st that these mechanisms explain the classic renal toxicities and peculiar tendinopathies associated
21         (225)Ac nanogenerators may result in renal toxicity and anemia at high doses.
22                                   Results If renal toxicity and clearance are not of direct treatment
23 in adult liver allotransplantation with less renal toxicity and less use of maintenance steroids.
24 carboplatin-based therapy had less long-term renal toxicity and ototoxicity.
25 isoproxil fumarate have been associated with renal toxicity and reduced bone mineral density.
26  efficacy against Leishmania spp, yet causes renal toxicity and requires intravenous administration,
27 ceiving these agents should be monitored for renal toxicity and the dose modified for renal insuffici
28 eta-analyses have raised questions regarding renal toxicity and the mortality associated with this ag
29 ly the possibility of chronic neurologic and renal toxicities, and the potential harm from delay of R
30                       Severe bone marrow and renal toxicity are less common adverse events.
31 stic infections, thromboembolic disease, and renal toxicities associated with high dose methotrexate.
32                  We review the mechanisms of renal toxicity associated with CNIs and the recent effor
33                                              Renal toxicity associated with small-molecule radionucli
34                           Seven patients had renal toxicity characterized by hypophosphatemia and/or
35 as to determine if a comparable reduction in renal toxicity could be achieved by performing the same
36 ppear to be at increased risk for developing renal toxicity due to administration of intravenous iodi
37 to safety studies in cynomolgus monkeys, and renal toxicity, due to compound precipitation, was obser
38              There was no grade 3 or greater renal toxicity during chemotherapy or grade 3 or greater
39 ation-response relationships for closure and renal toxicity, especially in select subgroups historica
40            We observed significantly reduced renal toxicity for peptide-labeled rapamycin micelles co
41 e evaluated the frequency of hematologic and renal toxicities from day 15 through 1-year post-SOT in
42 weeks), only transient liver toxicity and no renal toxicity had been observed.
43 a low incidence of long-term hematologic and renal toxicity, have been reported.
44  analyzing blood samples for hematologic and renal toxicity (hemoglobin, leukocytes, platelets, creat
45  outweighed the theoretical risk of liver or renal toxicity; however, additional studies are needed t
46 otoxicity occurred in 3 patients, and severe renal toxicity in 1 patient.
47 in 19 (4%), thrombocytopenia in 32 (7%), and renal toxicity in 22 (5%).
48  unrelated to disease (e.g., bone marrow and renal toxicity in 48% and maximal renal absorbed dose in
49 ductions in renal function and predictors of renal toxicity in a large open-label study of PrEP.
50 d not result in major additional TDF-related renal toxicity in HIV-infected patients.
51 ere used to study predictors of survival and renal toxicity in patients completing three or more trea
52  of TGF-beta in immunosuppression-associated renal toxicity in recipients of cardiac transplantation.
53 ut was more likely to cause grade 3, 4, or 5 renal toxicity (in 9 percent of patients, vs. 3 percent
54 ney dysfunction, as a proxy for drug induced renal toxicity, in rats.
55 environmental enrichment (EE) on cardiac and renal toxicity induced by 2 weeks of ketamine self-admin
56 ended dose of 90 mg, intravenously, monthly, renal toxicity is infrequent; however, higher doses have
57                                  The risk of renal toxicity may depend on the accumulation of CsA and
58 DA is a potent nephrotoxicant, and potential renal toxicity may require consideration when determinin
59 rmalities continue, to which FK 506-mediated renal toxicity might contribute.
60 thrombocytopenia with bleeding, grade 3 or 4 renal toxicity, neutropenic fever, or mucositis) was obs
61 ys and probably contributed to the long-term renal toxicity observed in surviving mice.
62                             In vivo, delayed renal toxicity occurred at >10-fold higher doses of S-F
63                                Dose-limiting renal toxicity occurred at 250 mg/m2, establishing the M
64                                              Renal toxicity occurred in 21 (15%) patients and was tem
65                                           No renal toxicity occurred with either radionuclide.
66                                 No grade 3/4 renal toxicity occurred.
67 learing efficiency (ICE) and ameliorated the renal toxicity of 2.
68 led metabolites may account for the reported renal toxicity of d-methamphetamine in humans.
69 ising to promote the recovery of cardiac and renal toxicity of ketamine.
70 romising approach that may help decrease the renal toxicity of other small fragments, the molecular w
71 ly to contribute to signaling underlying the renal toxicity of the AGAs.
72 ation, like CHOP(-/-) mice, are resistant to renal toxicity of the ER stress-inducing drug tunicamyci
73 ntive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw.
74 urable toxicity profile, including a lack of renal toxicity, patients with UBC, who are often older a
75                                  Leukopenia, renal toxicity, peripheral neurotoxicity, and CNS toxici
76 ided, thus preventing any clinically evident renal toxicity related to TAC.
77 herapies are introduced to treat cancer, new renal toxicities require proper diagnosis and management
78                                         This renal toxicity seems to be more prevalent among male pat
79 enal cells, and showed their application for renal toxicity studies.
80 lial growth factor-A (VEGF-A) associate with renal toxicity suggests that VEGF plays a role in the ma
81          Two patients developed grade 3 to 4 renal toxicity, three developed grade 3 CNS toxicity, on
82 cts, such as gastrointestinal ulceration and renal toxicity, through the inhibition of the constituti
83 erum creatinine, and 1 showed no evidence of renal toxicity (up to 5 y of follow-up).
84 ly 30% of patients experienced grades 2 to 4 renal toxicity, usually at doses targeting more than 40
85 eutic trial with N-acetylcysteine to reverse renal toxicity was attempted.
86                                         Mild renal toxicity was common before day 100; 63% of patient
87     Furthermore, as compared with aprotinin, renal toxicity was not observed with KD1-L17R.
88 ient neutropenia occurred, but no hepatic or renal toxicity was noted.
89                               No appreciable renal toxicity was observed at any dose level.
90 both FU/DOX and FU/STZ, and mild to moderate renal toxicity was reported in 40 (34.8%) of 115 patient
91                                           No renal toxicity was seen.
92                                No hepatic or renal toxicities were noted.
93 y was common, but deafness and pulmonary and renal toxicities were rare.
94 tolerated because of grade 4 neutropenia and renal toxicity, whereas the 14.15-mg/m(2) dose level was
95 ther developed grade 3 respiratory, CNS, and renal toxicity, which resolved.
96 de portability, no ionising radiation and no renal toxicity, with the great advantage of real-time im